ETV+ DRV/r + RAL in Treatment-Experienced Patients

TRIO Trial
**Study Design: TRIO**

- **Background**: Phase 2, non-comparative trial assessing safety and efficacy of an antiretroviral regimen containing etravirine, darunavir boosted with ritonavir, and raltegravir in adults with HIV and multidrug-resistant virus.

- **Inclusion Criteria (n = 103)**
  - Age ≥18 years
  - On stable ARV regimen for ≥8 weeks
  - HIV RNA >1000 copies/ml
  - Mutations allowed: ≥3 PI, ≥3 NRTI, ≤3 NNRTI
  - Naïve to etravirine, darunavir, and raltegravir

- **Treatment Arms**
  - Etravirine 200 mg bid + Darunavir 600 mg BID + Ritonavir 100mg bid + Raltegravir 400 mg bid + optimized background regimen (OBR)

*OBT = NRTIs +/- Enfuvirtide

**Trio Regimen**
- Etravirine + Darunavir + Ritonavir + Raltegravir + OBT (n = 103)

Etravirine + Darunavir/r + Raltegravir
TRIO: Result

Week 24 and 48: Virologic Response (Intention-to-treat Analysis)

Etravirine + Darunavir/r + Raltegravir
TRIO: Result

Week 24: Virologic Response (ITT Analysis), by Baseline HIV RNA

**Etravirine + Darunavir/r + Raltegravir**

**TRIO: Conclusions**

**Conclusion**: “In patients infected with multidrug-resistant virus who have few remaining treatment options, the combination of raltegravir, etravirine, and darunavir/ritonavir is well tolerated and is associated with a rate of virologic suppression similar to that expected in treatment-naive patients.”

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*